NorthView Acquisition Corp (NVAC)

[Devolution]

Last Thursday/Friday I sold off some NVACR (at just about cost) in order to pick up AXIM, as it dipped down to .15/.16.

Hopping to turn the AXIM back in at around a 4 to 5 cent gain per share (in the .20s) this week, and then turn that back into NVACR.

Problem is that I believe time is short.

Since it only took Peter O'Rouke 30 days to break the units (NVACU) into their separate components (NVAC, NVACW, and NVACR), it might only be 30 days until he announces his acquisition target.

The shares came out 12/23, then broke into separate pieces 1/21, so another 30 days is this coming Friday (2/19).

Going to be real close if I can pull this off - unless he delays in the acquisition announcement till the following week or later.

Interesting week coming up.

March 2020 - Axim finalized acquisition of Sapphire.

April 2021 - NorthView Registered.

December 2021 - NorthView IPO.

I feel that Peter (who is on the board at Axim) saw other biotechs that Axim was looking at and decided that since Axim could only afford to acquire one (Sapphire), he would (separate from Axim) bring the next best candidate public via a SPAC - but he waited until the pandemic looked like it was going to subside (ie: March 2020 was the beginning of the lockdowns).

Having waited 1 1/2 years, I think Peter knows his target already and is looking to work quickly.

Peter could announce as early as this coming Friday (February 19, 2022).